ALK-POZITIVNYY NEMELKOKLETOChNYY RAK LEGKOGO: NOVYE PATsIENTY I NOVYE VOZMOZhNOSTI LEKARSTVENNOGO LEChENIYa


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In non-small cell lung cancer (LC), special small subgroup of patients with ALK gene translocation in tumor is allocated. The modified gene encodes a synthesis of pathological protein, leading to pathological activation of ALK receptor on the membrane of malignant cells and tumor progression. Antitumor effect of crizotinib is determined by blockade of tyrosine kinases of intracellular domain of activated ALK receptor. Clinical studies on crizotinib have noted a high frequency (> 60 %) of complete and partial regression in chemoresistant metastatic ALK-positive lung cancer; median progression-free survival is more than 9 months. In phase III trial (PROFILE 1007), crizotinib as a 2nd line treatment of ALK-positive lung cancer was significantly more effective than standard chemotherapy, and significantly improved the quality of life of patients. Crizotinib is considered as a standard treatment for advanced ALK-positive lung cancer.

全文:

受限制的访问

作者简介

V. Breder

K. Laktionov

参考

  1. Webb T.R., Slavish J., George R.E., et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer The t(2; 5)(p23; q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia. 1989; 3(12): 866-70.
  2. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153): 561-66.
  3. Rikova K., Guo A., Zeng Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6): 1190-203.
  4. Takeuchi K., Choi Y.L., Togashi Y., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immune-histochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009; 15(9): 3143-49.
  5. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.et al. N. Engl. J. Med.2010; 363(18): 1693-703.
  6. Garber K. ALK, lung cancer, and personalized therapy: portent of the future. J. Natl. Cancer Inst. 2010; 102(10): 672-675. doi: 10.1093/jnci/djq184
  7. Rodig S., Shaw A.T., Costa D., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 2009; 15: 5216-23.
  8. Shaw A., Costa D., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27: 4247-53.
  9. Varella-Garcia, et al. IASLC 2011; Abs #005.01
  10. Varella-Garcia M., Berry L.D., Su P.F., et al. ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. ASCO 2012; Abs 7589.
  11. Atherly A.J., Camidge D.R. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer. 2012; 106(6): 1100-106.
  12. Lindeman N.I., et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thor. Oncol. 2013, doi; 10.1097/JTO.0b013e318290868f
  13. Zhang et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Molecular Cancer 2010; 9: Article 188.
  14. Huang et al., Changes in molecular profile following platinum chemotherapy in NSCLC. ASCO 2011; abstr 10518.
  15. Camidge D.R., Kono S.A., Flacco A., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010; 16(22): 5581-90.
  16. Thunnissen E., et al. EML4-ALK testing in nonsmall cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012; 461(3): 245-57.
  17. Mino-Kenudson M., Chirieac L.R., Law K. et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immune-histochemistry. Clin. Cancer Res. 2010; 16(5): 1561-71. doi: 10.1158/1078-0432.CCR-09-2845.
  18. Tan W., et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J. Clin. Oncol. 2010; 28: 15S. abstr 2596.
  19. Camidge D.R., Bang Y., Kwak E.L., et al. Progression-free survival from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer. J. Clin. Oncol. 2011; 29(suppl.): abstr 2501.
  20. Camidge D.R., Bang Y., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 2012; 13: 1011-19.
  21. Kim D.W., et al. Updated Results of a Global Phase II Study with Crizotinib in Advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) ESMO 2012; abstr 1230PD.
  22. Riely G.J., et al. IASLC Chicago Multidisciplinary Symp. in Thoracic Oncol. 2012; abstr 166.
  23. Solomon B., Chiappori A., Lamb A., et al. Preliminary Characterization of Visual Events Reported by Patients Receiving Crizotinib for the Treatment of Advanced ALK-positive Non-small Cell Lung Cancer. ECCO-ESMO 2011; Abs 3030.
  24. Besse B., Salgia R. Solomon B., et al. Visual Disturbances in Patients (Pts) with Anaplastic Lymphoma Kinase (ALK)-positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib ESMO 2012; Abstr. 1268P.
  25. Crino L., Kim D., Riely G.J., et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 2011; 29(suppl): abstr 7514.
  26. Weickhardt A.J., Rothman M.S., Salian-Mehta S., et al. Rapid onset hypogonadism secondary to crizotinib use in men with metastatic non-small cell lung cancer. Cancer. 2013. doi: 10.1002/cncr.28089.
  27. Ou S.H., et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged nonsmall cell lung cancer (NSCLC). J. Clin. Oncol. 2013; 31(suppl.): abstr.8032).
  28. Shaw A.T., Kim D.-W., Nakagawa K., et al. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N Engl J Med 2013. doi: 10.1056/NEJMoa1214886.
  29. NCCN guidelines, ver. 2, 2013. www.nccn.org

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##